Sanofi-Aventis, Intelliject Sign Licensing Agreement for Epinephrine Auto Injector

Sanofi-aventis U.S. announced Monday the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America.
Fox Business